Gain Therapeutics, Inc.
GANX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001819411
No open-market purchases or sales by Gain Therapeutics, Inc. insiders were filed in the last 90 days; 50 institutions reported holding it in 13F filings for Q2 2026, worth $18.6M in total; Greenlight Capital is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Gain Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Gain Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Goldstein Dov A MD | Director | – | Jul 17, 2026 | 1 |
| Nicaise Claude | Director | – | Jul 17, 2026 | 1 |
| Islam Khalid | Director | 50,000 | Jul 17, 2026 | 1 |
| Melincoff Gwen A | Director | – | Jul 17, 2026 | 1 |
| Riley Jeffrey Scott | Director | 30,000 | Jul 17, 2026 | 1 |
| Hasler Hans Peter | Director | – | Jul 17, 2026 | 1 |
| Mack Gene | CEO, President | 14,400 | Mar 26, 2026 | 1 |
| Fuggetta Gianluca | See Remark | – | Mar 26, 2026 | 1 |
| Richman Eric I | Director | 289,629 | Jun 25, 2025 | 0 |
| Alder Matthias | Chief Executive Officer | 21,140 | Mar 28, 2024 | 0 |
| Ballantyne Charles Evan | Chief Financial Officer | – | Apr 12, 2023 | 0 |
| Calabrese Salvatore | Chief Financial Officer | 3,000 | Mar 27, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2024 (view filing) | Aug 9 | 3 days | Mack GeneCFO and Interim CEO | PPurchase | +14.4K | $1.01 | +$14.5K | New position14.4K after | |
| Aug 12, 2024 (view filing) | Aug 9 | 3 days | Islam KhalidExecutive Chairman | PPurchase | +50.0K | $1.00 | +$50.0K | New position50.0K after | |
| Jul 1, 2024 (view filing) | Jul 1 | Same day | Richman Eric IDirector | PPurchase | +17.0K | $1.22 | +$20.7K | +6.2%289.6K after | 2 lots |
| Apr 1, 2024 (view filing) | Mar 28 | 4 days | Riley Jeffrey ScottDirector | PPurchase | +30.0K | $3.86 | +$115.8K | New position30.0K after | |
| Dec 22, 2023 (view filing) | Dec 21 | 1 day | Alder MatthiasChief Executive Officer | SSale | −206 | $2.46 | −$506.76 | −3.8%5.29K after | |
| Dec 14, 2023 (view filing) | Dec 7 | 7 daysLate | Alder MatthiasChief Executive Officer | SSale | −1.82K | $2.50 | −$4.55K | −27.3%4.86K after | |
| May 27, 2022 (view filing) | May 25 | 2 days | Richman Eric ICHIEF EXECUTIVE OFFICER | PPurchase | +2.48K | $2.58 | +$6.40K | +1.2%217.7K after | |
| May 23, 2022 (view filing) | May 19 | 4 days | Richman Eric ICHIEF EXECUTIVE OFFICER | PPurchase | +4.00K | $2.71 | +$10.8K | +2.0%206.0K after | |
| May 23, 2022 (view filing) | May 20 | 3 days | Richman Eric ICHIEF EXECUTIVE OFFICER | PPurchase | +9.26K | $2.83 | +$26.2K | +4.5%215.2K after | |
| May 23, 2022 (view filing) | May 19 | 4 days | Calabrese SalvatoreCHIEF FINANCIAL OFFICER | PPurchase | +3.00K | $2.70 | +$8.10K | New position3.00K after | Amended |
| Apr 21, 2022 (view filing) | Aug 16, 2021 | 248 days | Richman Eric IChief Executive Officer | PPurchase | +4.92K | $7.87 | +$38.7K | +2.3%216.8K after | Amended |